Maxygen and Astellas Ink Deal for Autoimmune Diseases

This post was commissioned on September 19, 2008, and it was categorized as License/Partnership.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Maxygen and Astellas announced a global agreement under which Astellas will receive worldwide rights to commercialize MAXY-4 lead candidates for all autoimmune diseases and transplant rejection. MAXY-4 is Maxygen’s preclinical program to create a next-generation CTLA4-Ig protein for rheumatoid arthritis, transplant rejection and other autoimmune indications.

The companies will co-develop MAXY-4 candidates for rheumatoid arthritis and other autoimmune diseases and Astellas will exclusively develop MAXY-4 candidates for transplant rejection. In addition, Maxygen has an option to co-promote any autoimmune therapeutic products developed under this alliance in North America.

Terms:
———————–
Upfront: $10M
Milestones: $160M prelaunch
Co-promotion option
Astellas pays first $10M of development cost; shared after

Theoretically Related Posts

October 24, 2008 -- Forest Laboratories, Inc. and Phenomix Corporation in $340 Million Diabetes Deal (0)
December 12, 2008 -- BMS Drops 240M For Codevelopment of 2 Exelixis Cancer Drugs (1)
November 10, 2008 -- BTG Inks $320 Million Preclinical Deal With Onyx (0)
October 30, 2008 -- EMD Serono Snags US license for Tesamorelin From Theratechnologies (0)
October 23, 2008 -- GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal (0)
September 10, 2008 -- GSK and Cellzome Announce Alliance over Kinase Technology (0)
May 13, 2008 -- BMS Picks Up KAI-9803 (0)
April 25, 2008 -- Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal (1)
February 18, 2009 -- Lilly Taps NeuroSearch For Preclinical Discovery Deal (0)
February 6, 2009 -- Idenix Take $34M Upfront From GSK For IDX899 (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: